32. Process according to claim 28, characterized in that the sensory cells of the inner ear are hair sensor cells.

33. Process according to claim 28, characterized in that the cell cycle inhibitor is a cyclin-dependent kinase inhibitor.

34. Process according to claim 33, characterized in that the cyclin-dependent kinase inhibitor is the cyclin-dependent kinase inhibitor $p27^{kip1}$.

35. Process according to claim 28, characterized in that the disease or disorder of the inner ear is a perceptive deafness.

36. Process according to claim 28, characterized in that the active ingredient is a least one peptide or at least one protein.

37. Process according to claim 28, characterized in that the active ingredient is at least one nucleic acid molecule.

38. Process according to claim 37, characterized in that the nucleic acid molecule codes for a peptide or a protein.

39. Process according to claim 37, characterized in that the nucleic acid molecule is a DNA molecule.

40. Process according to claim 39, characterized in that the nucleic acid molecule is a cDNA molecule.

41. Process according to claim 37, characterized in that the nucleic acid molecule is a RNA molecule.

42. Process according to claim 28, characterized in that the active ingredient is in the form of a vector.

43. Process according to claim 42, characterized in that the vector is a viral vector.

44. Process according to claim 43, characterized in that the virus is a retrovirus, an adenovirus or an adeno-associated virus.

45. Process according to claim 42, characterized in that the vector is a non-viral vector.

46. Process according to claim 37, characterized in that it is a nucleic acid molecule packed in a liposome or a lipoplex.

47. Process according to claim 28, characterized in that the active ingredient is used in a therapeutically active quantity.

48. Process according to claim 28, characterized in that the active ingredient is intended for local application.

49. Active ingredient for regenerating the sensory cells of the inner ear, characterized in the it is in a position to at least partly inhibit or eliminate the action of a cell cycle inhibitor present in the inner ear.

50. Active ingredient according to claim 49, characterized in that the cell cycle inhibitor is a cyclin-dependent kinase inhibitor.

51. Active ingredient according to claim 49, characterized in that it is at least one peptide or at least one protein.

52. Active ingredient according to claim 49, characterized in that it is a least one nucleic acid molecule.

53. Active ingredient according to claim 52, characterized in that the nucleic acid molecule is selected from the group consisting of a DNA molecule, cDNA molecule or RNA molecule.

54. Active ingredient according to claim 49, characterized in that the active ingredient is in the form of a vector or vehicle.

55. Pharmaceutical composition or medicament, characterized in that it contains at least one active ingredient able to inhibit or eliminate the action of a cell cycle inhibitor present in the inner ear in an active quantity and a pharmaceutically acceptable carrier.

56. Pharmaceutical composition or medicament according to claim 55, characterized in that the active ingredient is an active ingredient according to claim 50.

57. Process according to claim 37 wherein said nucleic acid molecule is recombined nucleic acid molecule.

58. Process according to claim 42 wherein said vector carries a nucleic acid molecule.

59. Active ingredient according to claim 49 wherein the sensory cells regenerated are hair sensory cells.

60. Active ingredient according to claim 50 wherein said cyclin-dependent kinase inhibitor is $p27^{kip1}$.